医学
新辅助治疗
结直肠癌
肿瘤科
化疗
放化疗
内科学
癌症
疾病
病态的
乳腺癌
作者
Elías Gomis Sellés,D. Gonsalves Pieretti,Paula Peleteiro Higuero,E. Gonzalez del Portillo,Virginia Morillo-Macías,M. J. Domínguez,Raquel Fuentes Mateos,F. López Campos,Ana Aurora Díaz-Gavela,G Ferraris,Felipe Couñago
出处
期刊:Future Oncology
[Future Medicine]
日期:2023-08-01
卷期号:19 (25): 1753-1768
被引量:1
标识
DOI:10.2217/fon-2023-0481
摘要
Locally advanced rectal cancer has traditionally been treated with chemoradiotherapy (CRT) followed by surgery and adjuvant chemotherapy. However, a new strategy, total neoadjuvant therapy, involves the administration of CRT and neoadjuvant chemotherapy with the aim of eradicating micrometastases earlier and achieving greater control of the disease. The use of total neoadjuvant therapy has shown higher rates of pathological complete response and resectability compared with CRT, including improved survival. Nevertheless, distant relapse is the main cause of morbidity and mortality in locally advanced rectal cancer. To address this, new biomarkers are being developed to predict disease response.
科研通智能强力驱动
Strongly Powered by AbleSci AI